» Articles » PMID: 38849868

PAX1 Methylation As a Robust Predictor: Developing and Validating a Nomogram for Assessing Endocervical Curettage (ECC) Necessity in Human Papillomavirus16/18-positive Women Undergoing Colposcopy

Overview
Publisher Biomed Central
Specialty Genetics
Date 2024 Jun 7
PMID 38849868
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: The major challenge in routine endocervical curettage (ECC) among Human Papillomavirus (HPV) 16/18-positive patients is that only a small fraction benefit. Nevertheless, current reported models often overestimate the validity and necessity of ECC, making it difficult to improve benefits for patients. This research hypothesized that assessing paired boxed gene 1 methylation levels (PAX1) and clinical characteristics could enhance the predictive accuracy of detecting additional high-grade squamous intraepithelial lesions or worse (HSIL +) through ECC that were not identified by colposcopy-directed biopsy (CDB).

Methods: Data from 134 women with HPV16/18 positivity undergoing CDB and ECC between April 2018 and April 2022 were collected and analyzed. Quantitative methylation-specific polymerase chain reaction (qMSP) was utilized to measure PAX1, expressed as ΔCp. Univariate and multivariate regression analyses were conducted to screen variables and select predictive factors. A nomogram was constructed using multivariate logistic regression to predict additional HSIL + detected by ECC. The discrimination, calibration, and clinical utility of the nomogram were evaluated using receiver operating characteristic curves (ROC) and the calibration plot.

Results: Age (odds ratio [OR], 5.654; 95% confidence interval [CI], 1.131-37.700), cytology (OR, 24.978; 95% CI, 3.085-540.236), and PAX1 methylation levels by grade (PAX1 grade) (OR, 7.801; 95% CI, 1.548-44.828) were independent predictive factors for additional detection of HSIL + by ECC. In HPV16/18-positive women, the likelihood of additional detection of HSIL + through ECC increased with the severity of cytological abnormalities, peaking at 43.8% for high-grade cytological lesions. Moreover, when cytological findings indicated low-grade lesions, PAX1 methylation levels were positively correlated with the additional detection of HSIL + by ECC (P value < 0.001). A nomogram prediction model was developed (area under curve (AUC) = 0.946; 95% CI, 0.901-0.991), demonstrating high sensitivity (90.9%) and specificity (90.5%) at the optimal cutoff point of 107. Calibration analysis confirmed the model's strong agreement between predicted and observed probabilities.

Conclusion: The clinical nomogram presented promising predictive performance for the additional detection of HSIL + through ECC among women with HPV16/18 infection. PAX1 methylation level could serve as a valuable tool in guiding individualized clinical decisions regarding ECC for patients with HPV 16/18 infection, particularly in cases of low-grade cytological findings.

Citing Articles

Comparing the performance of DeoxyriboNucleic Acid methylation analysis and cytology for detecting cervical (pre)cancer in women with high-risk human papillomavirus-positive status in a gynecologic outpatient population.

Tao H, Yu F, Yang L, Pei X, Mao S, Fan X BMC Cancer. 2024; 24(1):1352.

PMID: 39497123 PMC: 11536530. DOI: 10.1186/s12885-024-13126-4.

References
1.
Khan M, Werner C, Darragh T, Guido R, Mathews C, Moscicki A . ASCCP Colposcopy Standards: Role of Colposcopy, Benefits, Potential Harms, and Terminology for Colposcopic Practice. J Low Genit Tract Dis. 2017; 21(4):223-229. DOI: 10.1097/LGT.0000000000000338. View

2.
Fukuchi E, Fetterman B, Poitras N, Kinney W, Lorey T, Littell R . Risk of cervical precancer and cancer in women with cervical intraepithelial neoplasia grade 1 on endocervical curettage. J Low Genit Tract Dis. 2013; 17(3):255-60. DOI: 10.1097/LGT.0b013e31826ca4d9. View

3.
Collins G, Reitsma J, Altman D, Moons K . Transparent reporting of a multivariable prediction model for individual prognosis or diagnosis (TRIPOD): the TRIPOD statement. BMJ. 2015; 350:g7594. DOI: 10.1136/bmj.g7594. View

4.
Perkins R, Guido R, Castle P, Chelmow D, Einstein M, Garcia F . 2019 ASCCP Risk-Based Management Consensus Guidelines for Abnormal Cervical Cancer Screening Tests and Cancer Precursors. J Low Genit Tract Dis. 2020; 24(2):102-131. PMC: 7147428. DOI: 10.1097/LGT.0000000000000525. View

5.
Melnikow J, Nuovo J, Willan A, Chan B, HOWELL L . Natural history of cervical squamous intraepithelial lesions: a meta-analysis. Obstet Gynecol. 1998; 92(4 Pt 2):727-35. DOI: 10.1016/s0029-7844(98)00245-2. View